ÌÇÐÄvlog

This randomized clinical trial compares treatment with neoadjuvant modified FOLFIRINOX with or without hypofractionated radiation therapy with historical data and establishes standards for therapy in borderline resectable pancreatic ductal adenocarcinoma.

This nonrandomized clinical trial aims to determine whether neoadjuvant atezolizumab, docetaxel, trastuzumab, and pertuzumab therapy for ERBB2-positive early breast cancer warrants continuation to the next phase.

This measurable residual disease–adapted study examines the association of treatment with elotuzumab with weekly carfilzomib, lenalidomide, and dexamethasone without stem cell transplant with rates of stringent complete response and measurable residual disease–negativity in patients with newly diagnosed multiple myeloma.

This systematic review and meta-analysis used databases, such as PubMed, ProQuest, and Scopus, to investigate the association between the COVID-19 pandemic and decreased rates of breast, colorectal, and cervical cancer screening globally.

This systematic review and meta-analysis compares the performance of the log-rank test vs the MaxCombo and difference in restricted mean survival time tests in immuno-oncology trials.

This multicenter cohort study analyzes the associations between intratumoral microbiota and prognostication in patients with nasopharyngeal carcinoma.

This quality improvement study audits individual participant data sharing by pharmaceutical companies for anticancer medicines approved by the US Food and Drug Administration.